Jounce Therapeutics, Inc. Initial Public Offering
Davis Polk advised the lead book-running manager and representative of the underwriters in connection with its $101.9 million initial public offering of common stock of Jounce Therapeutics,…
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
Davis Polk Advises Roche on Its Sale of Florence, South Carolina, Manufacturing Site to Patheon
Davis Polk is advising Roche Holding Ltd. in connection with the sale of an active pharmaceutical ingredients manufacturing facility in Florence, South Carolina, to Patheon N.V. Under the…
iRhythm Technologies, Inc. Initial Public Offering
Davis Polk advised the joint book-running managers and representatives of the several underwriters on the initial public offering by iRhythm Technologies, Inc. iRhythm sold 7,238,235 shares…
Davis Polk Advises AC Immune SA on Its Initial Public Offering
Davis Polk advised AC Immune SA in connection with its $75.9 million U.S. initial public offering. AC Immune sold 6,900,000 of its common shares in the offering, which included 900,000…
Davis Polk Advises Aetna on the Sale of Medicare Advantage Assets to Molina Healthcare
Davis Polk is advising Aetna Inc. in connection with the sale by Aetna and Humana Inc. of certain of their respective Medicare Advantage assets to Molina Healthcare, Inc. for a total…
Patheon N.V. Initial Public Offering
Davis Polk advised the joint book-running managers and representatives of the several underwriters on the $719 million initial public offering by Patheon N.V. (“Patheon”). The IPO comprised…
McKesson formation of a new company with Change Healthcare Holdings
Davis Polk advised McKesson Corporation on its creation of a new health care information technology company, which will combine substantially all of Change Healthcare Holdings, Inc.’s…
Aeglea BioTherapeutics, Inc. Initial Public Offering
Davis Polk advised the joint book-running managers and representatives of the several underwriters on the $54.8 million initial public offering by Aeglea BioTherapeutics, Inc. Aeglea’s…
Corvus Pharmaceuticals, Inc. Initial Public Offering
Davis Polk advised the joint book-running managers and representatives of the several underwriters in the $70.5 million initial public offering by Corvus Pharmaceuticals, Inc. of 4,700,000…
BeiGene, Ltd. Initial Public Offering and NASDAQ Listing
Davis Polk advised the joint book-running managers and representatives of the underwriters in the $182.2 million initial public offering by BeiGene, Ltd. of 7,590,000 American Depositary…